

Miguel Casas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11483505/publications.pdf>

Version: 2024-02-01

123
papers

7,826
citations

76326

40
h-index

58581

82
g-index

133
all docs

133
docs citations

133
times ranked

12203
citing authors

#	ARTICLE	IF	CITATIONS
1	Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nature Genetics, 2013, 45, 984-994.	21.4	2,067
2	Analysis of shared heritability in common disorders of the brain. Science, 2018, 360, .	12.6	1,085
3	Joint Analysis of Psychiatric Disorders Increases Accuracy of Risk Prediction for Schizophrenia, Bipolar Disorder, and Major Depressive Disorder. American Journal of Human Genetics, 2015, 96, 283-294.	6.2	225
4	Efficacy of Methylphenidate for Adults with Attention-Deficit Hyperactivity Disorder. CNS Drugs, 2011, 25, 157-169.	5.9	192
5	Multicenter Analysis of the SLC6A3/DAT1 VNTR Haplotype in Persistent ADHD Suggests Differential Involvement of the Gene in Childhood and Persistent ADHD. Neuropsychopharmacology, 2010, 35, 656-664.	5.4	180
6	A Randomized, Placebo-Controlled Trial of Three Fixed Dosages of Prolonged-Release OROS Methylphenidate in Adults with Attention-Deficit/Hyperactivity Disorder. Biological Psychiatry, 2008, 63, 981-989.	1.3	167
7	Variability in the prevalence of adult ADHD in treatment seeking substance use disorder patients: Results from an international multi-center study exploring DSM-IV and DSM-5 criteria. Drug and Alcohol Dependence, 2014, 134, 158-166.	3.2	150
8	An independent components and functional connectivity analysis of resting state fMRI data points to neural network dysregulation in adult ADHD. Human Brain Mapping, 2014, 35, 1261-1272.	3.6	147
9	A Genetic Investigation of Sex Bias in the Prevalence of Attention-Deficit/Hyperactivity Disorder. Biological Psychiatry, 2018, 83, 1044-1053.	1.3	146
10	Validity of the Adult ADHD Self-Report Scale (ASRS) as a screener for adult ADHD in treatment seeking substance use disorder patients. Drug and Alcohol Dependence, 2013, 132, 587-596.	3.2	135
11	Psychiatric comorbidity in treatment-seeking substance use disorder patients with and without attention deficit hyperactivity disorder: results of the <sc>IASP</sc> study. Addiction, 2014, 109, 262-272.	3.3	129
12	Dissecting the Shared Genetic Architecture of Suicide Attempt, Psychiatric Disorders, and Known Risk Factors. Biological Psychiatry, 2022, 91, 313-327.	1.3	114
13	Attention deficit hyperactivity disorder in adults. World Journal of Biological Psychiatry, 2010, 11, 684-698.	2.6	113
14	A Double-Blind, Placebo-Controlled Study of Naltrexone in the Treatment of Alcohol-Dependence Disorder: Results from a Multicenter Clinical Trial. Alcoholism: Clinical and Experimental Research, 2002, 26, 1381-1387.	2.4	100
15	Striatal Dopaminergic D ₂ Receptor Density Measured by [¹²³ I]Iodobenzamide SPECT in the Prediction of Treatment Outcome of Alcohol-Dependent Patients. American Journal of Psychiatry, 2000, 157, 127-129.	7.2	94
16	Efficacy of Psychostimulant Drugs for Cocaine Dependence. , 2010, , CD007380.		89
17	Comorbid Attention-Deficit/Hyperactivity Disorder in Borderline Patients Defines an Impulsive Subtype of Borderline Personality Disorder. Journal of Personality Disorders, 2010, 24, 812-822.	1.4	84
18	Response inhibition and reward anticipation in medication-naïve adults with attention-deficit/hyperactivity disorder: A within-subject case-control neuroimaging study. Human Brain Mapping, 2012, 33, 2350-2361.	3.6	78

#	ARTICLE	IF	CITATIONS
19	New suggestive genetic loci and biological pathways for attention-deficit/hyperactivity disorder. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2015, 168, 459-470.	1.7	78
20	Prevalence and Predictors of Posttraumatic Stress Symptomatology Among Burn Survivors. <i>Journal of Burn Care and Research</i> , 2016, 37, e79-e89.	0.4	76
21	Cannabinoids therapeutic use: what is our current understanding following the introduction of THC, THC:CBD oromucosal spray and others?. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 443-455.	3.1	66
22	Efficacy of central nervous system stimulant treatment for cocaine dependence: a systematic review and meta-analysis of randomized controlled clinical trials. <i>Addiction</i> , 2007, 102, 1871-1887.	3.3	65
23	Enhanced neural activity in frontal and cerebellar circuits after cognitive training in children with attention-deficit/hyperactivity disorder. <i>Human Brain Mapping</i> , 2010, 31, 1942-1950.	3.6	64
24	Case-Control Study of Six Genes Asymmetrically Expressed in the Two Cerebral Hemispheres: Association of BAIAP2 with Attention-Deficit/Hyperactivity Disorder. <i>Biological Psychiatry</i> , 2009, 66, 926-934.	1.3	59
25	Case-Control Genome-Wide Association Study of Persistent Attention-Deficit Hyperactivity Disorder Identifies FBXO33 as a Novel Susceptibility Gene for the Disorder. <i>Neuropsychopharmacology</i> , 2015, 40, 915-926.	5.4	59
26	Attention-deficit/hyperactivity disorder and lifetime cannabis use: genetic overlap and causality. <i>Molecular Psychiatry</i> , 2020, 25, 2493-2503.	7.9	59
27	Amphetamines for Attention Deficit Hyperactivity Disorder (ADHD) in adults. <i>The Cochrane Library</i> , 2011, , CD007813.	2.8	58
28	Cocaine Use Immediately Prior to Entry in an Inpatient Heroin Detoxification Unit as a Predictor of Discharges Against Medical Advice. <i>American Journal of Drug and Alcohol Abuse</i> , 1997, 23, 267-279.	2.1	56
29	Decreased serum levels of brain-derived neurotrophic factor in adults with attention-deficit hyperactivity disorder. <i>International Journal of Neuropsychopharmacology</i> , 2013, 16, 1267-1275.	2.1	56
30	A Double-Blind, Placebo-Controlled Study of Olanzapine in the Treatment of Alcohol-Dependence Disorder. <i>Alcoholism: Clinical and Experimental Research</i> , 2004, 28, 736-745.	2.4	54
31	History of sexual, emotional or physical abuse and psychiatric comorbidity in substance-dependent patients. <i>Psychiatry Research</i> , 2015, 229, 743-749.	3.3	54
32	Cocaine Use in Europe – A Multi-Centre Study. <i>European Addiction Research</i> , 2004, 10, 139-146.	2.4	50
33	Efficacy of Opiate Maintenance Therapy and Adjunctive Interventions for Opioid Dependence with Comorbid Cocaine Use Disorders: A Systematic Review and Meta-Analysis of Controlled Clinical Trials. <i>American Journal of Drug and Alcohol Abuse</i> , 2009, 35, 339-349.	2.1	50
34	Genome-wide copy number variation analysis in adult attention-deficit and hyperactivity disorder. <i>Journal of Psychiatric Research</i> , 2014, 49, 60-67.	3.1	50
35	Brain-derived neurotrophic factor serum levels in cocaine-dependent patients during early abstinence. <i>European Neuropsychopharmacology</i> , 2013, 23, 1078-1084.	0.7	49
36	Effect of Switching Drug Formulations from Immediate-Release to Extended-Release OROS Methylphenidate. <i>CNS Drugs</i> , 2008, 22, 603-611.	5.9	47

#	ARTICLE	IF	CITATIONS
37	Group Therapy for Adolescents With Attention-Deficit/Hyperactivity Disorder: A Randomized Controlled Trial. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2015, 54, 275-282.	0.5	46
38	Validez de criterio y concurrente de la versión española de la Conners Adult ADHD Diagnostic Interview for DSM-IV. <i>Revista De Psiquiatría Y Salud Mental</i> , 2012, 5, 229-235.	1.8	45
39	Psychiatric comorbidities in opioid-dependent patients undergoing a replacement therapy programme in Spain: The PROTEUS study. <i>Psychiatry Research</i> , 2016, 243, 174-181.	3.3	44
40	Training-induced neuroanatomical plasticity in ADHD: A tensor-based morphometric study. <i>Human Brain Mapping</i> , 2011, 32, 1741-1749.	3.6	43
41	Adult ADHD Screening in Alcohol-Dependent Patients Using the Wender Utah Rating Scale and the Adult ADHD Self-Report Scale. <i>Journal of Attention Disorders</i> , 2015, 19, 328-334.	2.6	43
42	Attention deficit hyperactivity disorder in cocaine-dependent adults: A psychiatric comorbidity analysis. <i>American Journal on Addictions</i> , 2013, 22, 466-473.	1.4	42
43	Evaluation of single nucleotide polymorphisms in the miR-183-96-182 cluster in adulthood attention-deficit and hyperactivity disorder (ADHD) and substance use disorders (SUDs). <i>European Neuropsychopharmacology</i> , 2013, 23, 1463-1473.	0.7	38
44	Rethinking Dual Disorders/Pathology. <i>Addictive Disorders and Their Treatment</i> , 2013, 12, 1-10.	0.5	34
45	Laminar Thickness Alterations in the Fronto-Parietal Cortical Mantle of Patients with Attention-Deficit/Hyperactivity Disorder. <i>PLoS ONE</i> , 2012, 7, e48286.	2.5	32
46	Predictors of treatment outcome in adults with ADHD treated with OROS® methylphenidate. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2011, 35, 554-560.	4.8	31
47	Epigenetic signature for attention-deficit/hyperactivity disorder: identification of miR-26b-5p, miR-185-5p, and miR-191-5p as potential biomarkers in peripheral blood mononuclear cells. <i>Neuropsychopharmacology</i> , 2019, 44, 890-897.	5.4	31
48	Addressing the lack of studies in attention-deficit/hyperactivity disorder in adults. <i>Expert Review of Neurotherapeutics</i> , 2014, 14, 553-567.	2.8	30
49	Emotional lability: The discriminative value in the diagnosis of attention deficit/hyperactivity disorder in adults. <i>Comprehensive Psychiatry</i> , 2014, 55, 1712-1719.	3.1	30
50	Efficacy of indirect dopamine agonists for psychostimulant dependence: A systematic review and meta-analysis of randomized controlled trials. <i>Journal of Substance Abuse Treatment</i> , 2011, 40, 109-122.	2.8	29
51	ADGRL3 (LPHN3) variants predict substance use disorder. <i>Translational Psychiatry</i> , 2019, 9, 42.	4.8	29
52	Attention-deficit hyperactivity disorder in chronic fatigue syndrome patients. <i>Psychiatry Research</i> , 2012, 200, 748-753.	3.3	28
53	Evaluation of common variants in 16 genes involved in the regulation of neurotransmitter release in ADHD. <i>European Neuropsychopharmacology</i> , 2013, 23, 426-435.	0.7	28
54	International Consensus Statement for the Screening, Diagnosis, and Treatment of Adolescents with Concurrent Attention-Deficit/Hyperactivity Disorder and Substance Use Disorder. <i>European Addiction Research</i> , 2020, 26, 223-232.	2.4	28

#	ARTICLE	IF	CITATIONS
55	Prevalence and risk factors of psychotic symptoms in cocaine-dependent patients. <i>Actas Espanolas De Psiquiatria</i> , 2012, 40, 187-97.	0.1	27
56	Efficacy and safety of prolonged-release OROS methylphenidate in adults with attention deficit/hyperactivity disorder: A 13-week, randomized, double-blind, placebo-controlled, fixed-dose study. <i>World Journal of Biological Psychiatry</i> , 2013, 14, 268-281.	2.6	26
57	Changes in brain-derived neurotrophic factor (BDNF) during abstinence could be associated with relapse in cocaine-dependent patients. <i>Psychiatry Research</i> , 2015, 225, 309-314.	3.3	26
58	Achieving Remission as a Routine Goal of Pharmacotherapy in Attention-Deficit Hyperactivity Disorder. <i>CNS Drugs</i> , 2011, 25, 17-36.	5.9	25
59	Differences in the association between childhood trauma history and borderline personality disorder or attention deficit/hyperactivity disorder diagnoses in adulthood. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2017, 267, 541-549.	3.2	25
60	Genome-wide association meta-analysis of age at first cannabis use. <i>Addiction</i> , 2018, 113, 2073-2086.	3.3	24
61	Stimulant drugs trigger transient volumetric changes in the human ventral striatum. <i>Brain Structure and Function</i> , 2014, 219, 23-34.	2.3	23
62	Epidemiology of psychiatric morbidity among migrants compared to native born population in Spain: a controlled study. <i>General Hospital Psychiatry</i> , 2013, 35, 93-99.	2.4	22
63	Cocaine-Induced Psychosis and Impulsivity in Cocaine-Dependent Patients. <i>Journal of Addictive Diseases</i> , 2013, 32, 263-273.	1.3	22
64	Clinical differences between cocaine-induced psychotic disorder and psychotic symptoms in cocaine-dependent patients. <i>Psychiatry Research</i> , 2014, 216, 398-403.	3.3	22
65	Cortisol Response to Stress in Adults with Attention Deficit Hyperactivity Disorder. <i>International Journal of Neuropsychopharmacology</i> , 2015, 18, pyv027.	2.1	21
66	Professionals' perception on the management of patients with dual disorders. <i>Patient Preference and Adherence</i> , 2016, Volume 10, 1855-1868.	1.8	21
67	The Fenix II study: A longitudinal study of psychopathology among burn patients. <i>Burns</i> , 2016, 42, 1201-1211.	1.9	21
68	Relationship between cocaine use and mental health problems in a sample of European cocaine powder or crack users. <i>World Psychiatry</i> , 2005, 4, 173-6.	10.4	21
69	Relationship between poor decision-making process and fatigue perception in Parkinson's disease patients. <i>Journal of the Neurological Sciences</i> , 2014, 337, 167-172.	0.6	20
70	Safety and tolerability of flexible dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. <i>Neuropsychiatric Disease and Treatment</i> , 2009, 5, 457.	2.2	19
71	Dopamine receptor DRD4 gene and stressful life events in persistent attention deficit hyperactivity disorder. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2015, 168, 480-491.	1.7	18
72	Alcohol use disorder and cognitive impairment in old age patients: A 6 months follow-up study in an outpatient unit in Barcelona. <i>Psychiatry Research</i> , 2018, 261, 361-366.	3.3	18

#	ARTICLE	IF	CITATIONS
73	Diferencias de género epidemiológicas y diagnósticas según eje I en pacientes con Patología Dual. Revista De Psicología De La Salud, 2011, 23, 165.	0.5	18
74	Confirmatory Factor Analysis of Borderline Personality Disorder symptoms based on two different interviews: The Structured Clinical Interview for DSM-IV Axis I Disorder and the Revised Diagnostic Interview for Borderlines. Psychiatry Research, 2011, 190, 304-308.	3.3	17
75	Serum Brain-Derived Neurotrophic Factor Levels and Cocaine-Induced Transient Psychotic Symptoms. Neuropsychobiology, 2013, 68, 146-155.	1.9	17
76	Neuroticism Associated with Cocaine-Induced Psychosis in Cocaine-Dependent Patients: A Cross-Sectional Observational Study. PLoS ONE, 2014, 9, e106111.	2.5	17
77	Changes in the serum levels of brain-derived neurotrophic factor in adults with attention deficit hyperactivity disorder after treatment with atomoxetine. Psychopharmacology, 2014, 231, 1389-1395.	3.1	17
78	Criteria and Concurrent Validity of Adult ADHD Section of the Psychiatry Research Interview for Substance and Mental Disorders. Journal of Attention Disorders, 2015, 19, 999-1006.	2.6	17
79	Functioning Assessment Short Test (FAST): validity and reliability in adults with attention-deficit/hyperactivity disorder. European Archives of Psychiatry and Clinical Neuroscience, 2014, 264, 719-727.	3.2	16
80	Dual Diagnosis Resource Needs in Spain: A National Survey of Professionals. Journal of Dual Diagnosis, 2014, 10, 84-90.	1.2	15
81	Exploring the clinical validity of borderline personality disorder components. Comprehensive Psychiatry, 2013, 54, 34-40.	3.1	14
82	Effectiveness of Inhaled Loxapine in Dual-Diagnosis Patients: A Case Series. Clinical Neuropharmacology, 2016, 39, 206-209.	0.7	14
83	Borderline Personality Disorder and Personality Inventory for DSM-5 (PID-5): Dimensional personality assessment with DSM-5. Comprehensive Psychiatry, 2016, 70, 105-111.	3.1	14
84	Integrative genomic analysis of methylphenidate response in attention-deficit/hyperactivity disorder. Scientific Reports, 2018, 8, 1881.	3.3	14
85	Severity factors associated with borderline personality disorder among misusers in an outpatient sample in Spain. Journal of Addictive Diseases, 2017, 36, 93-96.	1.3	13
86	Criterion and concurrent validity of Conners Adult ADHD Diagnostic Interview for DSM-IV (CAADID) Spanish version. Revista De Psiquiatría Y Salud Mental (English Edition), 2012, 5, 229-235.	0.3	12
87	Psychotic Symptoms of Cocaine Self-Injectors in a Harm Reduction Program. Substance Abuse, 2013, 34, 118-121.	2.3	12
88	Protocols of Dual Diagnosis Intervention in Schizophrenia. Addictive Disorders and Their Treatment, 2011, 10, 131-154.	0.5	11
89	Gender Differences in Dually Diagnosed Outpatients. Substance Abuse, 2013, 34, 78-80.	2.3	11
90	Epidemiology of substance abuse among migrants compared to native born population in primary care. American Journal on Addictions, 2014, 23, 337-342.	1.4	11

#	ARTICLE	IF	CITATIONS
91	The apomorphine test in heroin addicts. <i>Addiction</i> , 1995, 90, 831-835.	3.3	11
92	Clinical differences between cocaine-dependent patients with and without antisocial personality disorder. <i>Psychiatry Research</i> , 2016, 246, 587-592.	3.3	10
93	OROS methylphenidate for the treatment of adults with attention-deficit/hyperactivity disorder. <i>Expert Review of Neurotherapeutics</i> , 2009, 9, 1121-1131.	2.8	7
94	Feasibility of Double-Blind Clinical Trials with Oral Diacetylmorphine: A Randomized Controlled Phase II Study in an Inpatient Setting. <i>European Addiction Research</i> , 2012, 18, 279-287.	2.4	7
95	Transcriptome profiling in adult attention-deficit hyperactivity disorder. <i>European Neuropsychopharmacology</i> , 2020, 41, 160-166.	0.7	7
96	Treatment adherence to treatment in substance users referred from Psychiatric Emergency service to outpatient treatment. <i>Actas Espanolas De Psiquiatria</i> , 2012, 40, 63-9.	0.1	7
97	Perception of Spanish professionals on therapeutic adherence of dual diagnosis patients. <i>Actas Espanolas De Psiquiatria</i> , 2013, 41, 319-29.	0.1	7
98	Childhood trauma in Chronic Fatigue Syndrome: focus on personality disorders and psychopathology. <i>Comprehensive Psychiatry</i> , 2015, 62, 13-19.	3.1	6
99	Genome-wide analysis of emotional lability in adult attention deficit hyperactivity disorder (ADHD). <i>European Neuropsychopharmacology</i> , 2019, 29, 795-802.	0.7	6
100	Validity of the ADHD module of the Mini International Neuropsychiatric Interview PLUS for screening of adult ADHD in treatment seeking substance use disorder patients: ADHD screening with MINI-Plus. <i>Revista De Psiquiatria Y Salud Mental</i> , 2020, , .	1.8	6
101	Fumar en las psicosis afectivas: revisión sobre el consumo de nicotina en el trastorno bipolar y esquizoafectivo. <i>Revista De Psicología De La Salud</i> , 2011, 23, 65.	0.5	6
102	Cocaine-induced Psychosis and Brain-derived Neurotrophic Factor in Patients with Cocaine Dependence: Report of Two Cases. <i>Clinical Psychopharmacology and Neuroscience</i> , 2016, 14, 109-113.	2.0	6
103	Comorbid personality disorders in chronic fatigue syndrome patients: a marker of psychopathological severity. <i>Actas Espanolas De Psiquiatria</i> , 2015, 43, 58-65.	0.1	6
104	Impulsive clinical profile of Borderline Personality Disorder with comorbid Substance Use Disorder. <i>Actas Espanolas De Psiquiatria</i> , 2016, 44, 145-52.	0.1	6
105	The apomorphine test: a biological marker for heroin dependence disorder?. <i>Addiction Biology</i> , 2002, 7, 421-426.	2.6	5
106	Professionals' perceptions about healthcare resources for co-occurring disorders in Spain. <i>International Journal of Mental Health Systems</i> , 2014, 8, 35.	2.7	5
107	Dual Disorders: A Clinical Perspective. <i>Addictive Disorders and Their Treatment</i> , 2017, 16, 175-179.	0.5	5
108	Toward a Better Understanding of Attention-Deficit/Hyperactivity Disorder Across the Lifespan. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , 2013, 52, 119-120.	0.5	4

#	ARTICLE	IF	CITATIONS
109	Assessing knowledge and attitudes towards addictions in medical residents of a general hospital. <i>Drugs: Education, Prevention and Policy</i> , 2015, 22, 457-462.	1.3	4
110	Driving and legal status of Spanish opioid-dependent patients. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2013, 8, 19.	2.2	3
111	Prevalence of attention deficit/hyperactivity disorder symptoms in outpatient adolescents and young adults with other psychiatric disorders refractory to previous treatments. <i>Revista De Psiquiatría Y Salud Mental (English Edition)</i> , 2014, 7, 104-112.	0.3	3
112	Borderline Personality Disorder (BPD) diagnosis with the self-report Personality Diagnostic Questionnaire-4+ (PDQ-4+): confirmation of the 3-factor structure. <i>Actas Espanolas De Psiquiatria</i> , 2012, 40, 57-62.	0.1	3
113	Study of prevalence of Personality Disorders in inmate men sample with Substance Use Disorders using of PDQ-4+ Self-Report. <i>Actas Espanolas De Psiquiatria</i> , 2016, 44, 178-82.	0.1	3
114	Reliability of the Beck Depression Inventory in opiate-dependent patients. <i>Journal of Substance Use</i> , 0, 1-6.	0.7	2
115	Sex differences in an old adult sample with substance use disorder: A 6 months follow-up study. <i>Psychiatry Research</i> , 2018, 270, 1157-1165.	3.3	2
116	A Double-Blind, Placebo-Controlled Study of Naltrexone in the Treatment of Alcohol-Dependence Disorder: Results from a Multicenter Clinical Trial. <i>Alcoholism: Clinical and Experimental Research</i> , 2002, 26, 1381-1387.	2.4	2
117	The SCID-II and DIB-R interviews: diagnostic association with poor outcome risk factors in Borderline Personality Disorder. <i>Psicothema</i> , 2012, 24, 523-8.	0.9	2
118	Professional perception of clozapine use in patients with dual psychosis. <i>Actas Espanolas De Psiquiatria</i> , 2020, 48, 99-105.	0.1	2
119	Reply to the Letter to the Editor: "Depression symptoms in burn patients". <i>Burns</i> , 2015, 41, 1895-1896.	1.9	0
120	¿El trastorno por déficit de atención con hiperactividad es siempre destructivo?. <i>Revista Espanola De Medicina Legal</i> , 2015, 41, 45-46.	0.1	0
121	Chapitre 1. Introduction à la notion de comorbidité et concept de dual diagnosis. , 2014, , 1-10.		0
122	Bipolar Disorders and Co-Occurring Addictions. , 2015, , 1959-1970.		0
123	Relevant Differences in Perception and Knowledge of Professionals in Different Spanish Autonomous Communities Regarding Availability of Resources for Patients with Dual disorders. <i>Actas Espanolas De Psiquiatria</i> , 2016, 44, 1-12.	0.1	0